SML2352
Aramchol
≥98% (HPLC)
别名:
Arachidyl amido cholanoic acid, (3β,5β,7α12α)-7,12-Dihydroxy-3-[(1-oxoeicosyl)amino]cholan-24-oic acid, 3β-arachidyl-amido, 7α-12α-dihydroxy, 5β-cholan-24-oic acid, C20-FABAC
InChI key
SHKXZIQNFMOPBS-OOMQYRRCSA-N
SMILES string
CCCCCCCCCCCCCCCCCCCC(N[C@@H]1C[C@](C[C@@H](O)[C@]2([H])[C@]3([H])C[C@H](O)[C@@]4(C)[C@@]2([H])CC[C@]4([H])[C@@H](CCC(O)=O)C)([H])[C@]3(C)CC1)=O
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
Arachidyl amido cholanoic acid (Aramchol) is a cholesterol solubilizer that has the potential to prevent and dissolves cholesterol gallstones in inbred mice and in human gallbladder bile ex vivo.
Aramchol is a bile salt fatty acid conjugate (BAFAC) of arachidic acid and cholic acid. It has been shown to reduce liver fat by a dual mechanism of action. It inhibits the activity of liver stearoyl coenzyme A desaturase 1 (SCD1), decreasing the synthesis of fatty acids. In addition, it activates cholesterol efflux by stimulating the adenosine triphosphate–binding cassette transporter A1 (ABCA1). Aramchol has been investigated for treatment for nonalcoholic steatohepatitis, or NASH.
SCD1 inhibitor and ABCA1 activator
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
D A Joyce et al.
Annals of the rheumatic diseases, 50(12), 913-914 (1991-12-01)
A double blind, placebo controlled trial examined the effects of folinic acid on the efficacy and toxicity of methotrexate in 27 patients with rheumatoid arthritis. Clinical and laboratory indices of disease activity worsened significantly in the 13 patients treated with
Rifaat Safadi et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 12(12), 2085-2091 (2014-05-13)
We investigated the effects of the fatty acid-bile acid conjugate 3β-arachidyl-amido, 7α-12α-dihydroxy, 5β-cholan-24-oic acid (Aramchol; Trima Israel Pharmaceutical Products Ltd, Maabarot, Israel) in a phase 2 trial of patients with nonalcoholic fatty liver disease (NAFLD). We performed a randomized, double-blind
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持